AbCellera Biologics Overview
AbCellera Biologics (ABCL) has a ROE of -18.38%, below the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-18.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
AbCellera Biologics (ABCL) currently reports a ROE of -18.38%. That is below the sector sector average of -5.68%. Use the charts on this page to explore AbCellera Biologics's ROE history and peer comparisons.
AbCellera Biologics's ROE of -18.38% is lower than the its sector sector average of -5.68%. That is roughly 223.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but AbCellera Biologics's current -18.38% should be judged against industry norms (sector average: -5.68%) and against ABCL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -18.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.68%. From there, open related valuation or income-statement pages for AbCellera Biologics, and consider following ABCL for alerts when major investors trade the stock.
